With markets stabilizing and investors moving back to high-growth names, a handful of companies are standing out for their strong momentum, improving fundamentals, and clear catalysts ahead. This week, three stocks, including BridgeBio Pharma (BBIO), Zscaler (ZS), and Oracle (ORCL), look well‑positioned thanks to stronger demand trends and bullish analyst sentiment.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Using the TipRanks Stock Screener tool, we picked these three stocks because they have received a “Strong Buy” consensus rating from analysts. Also, these stocks have more than 35% upside potential in the next twelve months.
Let’s look at why BBIO, ZS, and ORCL are the best stocks to watch this week. (Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.)
1. BridgeBio Pharma (BBIO)
BridgeBio Pharma is a major biotech name, backed by a deep pipeline focused on genetic diseases and oncology. The company is advancing multiple late‑stage programs, including therapies for transthyretin amyloidosis and FGFR‑driven cancers, and has built a strong track record of hitting clinical and regulatory milestones. Its expanding portfolio and steady trial progress continue to aid bullish analyst sentiment.
Today, H.C. Wainwright’s Ram Selvaraju kept a Buy rating and $100 target on BBIO, citing long patent runway for acoramidis, delayed tafamidis competition, and multiple upcoming regulatory catalysts across its pipeline.
Overall, BBIO stock has a Strong Buy consensus rating based on 18 Buys assigned in the last three months. At $102.56, the average BridgeBio stock price target implies a 37.62% upside potential.
2. Zscaler (ZS)
Zscaler remains a top Wall Street cybersecurity pick thanks to its strength in zero-trust and cloud-native security. The company is viewed as a high‑growth winner from rising cloud adoption, AI‑driven security automation, and escalating cyber threats. Strong billings momentum and continued large‑customer wins might support further upside.
Citizens analyst Trevor Walsh reiterated his Outperform rating and $290 price target on Zscaler, saying its inclusion in OpenAI’s Trusted Access for Cyber program strengthens its position among leading platform-consolidation players alongside CrowdStrike (CRWD) and Palo Alto Networks (PANW).
Wall Street’s consensus rating for Zscaler stock is Strong Buy based on 28 Buys and six Holds. The average analyst price target of $228.13 implies an upside potential of 70.1% from the current levels.
3. Oracle (ORCL)
Oracle earns a place on this week’s buy list thanks to a surge of bullish analyst coverage framing the company as a foundational AI infrastructure provider. In fiscal Q3, Oracle’s multi‑cloud database revenue surged 531% year‑over‑year, reflecting its competitive edge in AI workloads and cloud integration.
Recently, Wedbush’s Daniel Ives initiated coverage with an Outperform and a $225 price target, arguing the market is misreading Oracle’s AI‑driven capex cycle. He highlighted 84% cloud infrastructure revenue growth and a 325% jump in remaining performance obligations to $553 billion, signaling massive contract-backed demand.
On TipRanks, analysts have a Strong Buy consensus rating on ORCL stock based on 28 Buys and six Holds assigned in the past three months. Further, the average Oracle price target of $244.21 per share implies 41.19% upside potential.
